Fresenius Group is a global healthcare company with €21.5 billion in annual revenue that develops and operates system-critical products and services for patients with acute and chronic illnesses. Operating across more than 100 years, the group serves approximately 4.5 million patients worldwide through its major divisions: Fresenius Kabi, which produces therapies and nutritional products for critically and chronically ill patients; Fresenius Helios, Europe's largest private hospital operator; and Fresenius Medical Care, the world's leading provider of dialysis products and services.
The group employs approximately 176,000 people (excluding Fresenius Medical Care) and maintains operations across Europe, the Americas, and other global markets. Fresenius competes in pharmaceuticals, biopharmaceuticals, medical devices, clinical nutrition, and care provision, positioning itself as a diversified supplier across the healthcare spectrum rather than a specialist in any single domain.
The company's stated commitment centres on making healthcare affordable, accessible, and innovative. Its scale and product portfolio mean Fresenius operates in both direct patient care through hospital networks and dialysis clinics, and in the development of medications and medical products that reach healthcare systems worldwide.
